The Texas Heart Institute at Baylor College of Medicine congratulates Dr. Christie Ballantyne on co-authoring a newly published study in the New England Journal of Medicine evaluating enlicitide, an investigational oral PCSK9 inhibitor with the potential to advance lipid management and cardiovascular prevention.
In this large, multinational clinical trial, enlicitide produced an approximately 57% reduction in LDL cholesterol at 24 weeks compared with placebo, with additional improvements in non-HDL cholesterol, apolipoprotein B, and lipoprotein(a), key drivers of cardiovascular risk. Safety outcomes were similar between treatment and placebo groups. Navar et al NEJM Feb 2026 Lipids.
This research highlights the promise of oral PCSK9 inhibition to help close treatment gaps for patients who remain above recommended LDL targets, while reinforcing THI’s legacy of leading research that advances cardiovascular care and improves patient outcomes.
Read the full article here.
Visit U.S. News & World Report
